IDEXX Laboratories, Inc. $IDXX Shares Bought by Cibc World Market Inc.

Cibc World Market Inc. lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 208.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,857 shares of the company’s stock after buying an additional 16,115 shares during the quarter. Cibc World Market Inc.’s holdings in IDEXX Laboratories were worth $16,140,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Marietta Investment Partners LLC raised its position in IDEXX Laboratories by 185.2% during the fourth quarter. Marietta Investment Partners LLC now owns 1,383 shares of the company’s stock worth $936,000 after acquiring an additional 898 shares during the period. CIBC Asset Management Inc increased its stake in shares of IDEXX Laboratories by 28.0% during the fourth quarter. CIBC Asset Management Inc now owns 37,818 shares of the company’s stock worth $25,585,000 after purchasing an additional 8,274 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of IDEXX Laboratories by 16.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 831,911 shares of the company’s stock worth $562,813,000 after purchasing an additional 119,969 shares in the last quarter. Bridges Investment Management Inc. raised its position in shares of IDEXX Laboratories by 36.6% during the 4th quarter. Bridges Investment Management Inc. now owns 541 shares of the company’s stock worth $366,000 after purchasing an additional 145 shares during the last quarter. Finally, Dynasty Wealth Management LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at about $237,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.5%

Shares of IDEXX Laboratories stock opened at $562.16 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock’s 50 day simple moving average is $563.05 and its 200-day simple moving average is $632.14. The stock has a market cap of $44.34 billion, a P/E ratio of 41.40, a P/E/G ratio of 3.09 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. Piper Sandler cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. UBS Group lowered their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.